• Explore /
  • Poster
  • / A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients: The RAMTAS trial of the German AIO (KRK-0316).

A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients: The RAMTAS trial of the German AIO (KRK-0316).

Abstract Poster

Authors

Stefan Kasper

Stefan Kasper

University Hospital Essen, Essen, Germany

Stefan Kasper , Gerrit zur Hausen , Alexander Stein , Sebastian Stintzing , Andreas Berger , Sonja Loges , Ralf Hofheinz , Tanja Trarbach , Ullrich Graeven , Ludwig Fischer von Weikersthal , Thorsten Oliver Goetze , Volker A. Hagen , Susen Burock , Albrecht Hoffmeister , Tobias Nicolaas Dechow , Claudia Pauligk , Isabel Virchow , Jens T Siveke , Salah-Eddin Al-Batran , Martin H. Schuler

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT03520946

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS3617)

DOI

10.1200/JCO.2019.37.15_suppl.TPS3617

Abstract #

TPS3617

Poster Bd #

108a

Abstract Disclosures

Similar Posters

First Author: Marc Van Den Eynde

First Author: Yuki Matsubara

First Author: Helena Anna Taflin

Poster

2014 Gastrointestinal Cancers Symposium

Cost differential among systemic therapies for colon cancer.

Cost differential among systemic therapies for colon cancer.

First Author: Hasan Nadeem